Clinical trial · Interventional
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
NCT00514267CI-TRIAL-00018816completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the feasibility and safety of administering YM155 in combination with docetaxel
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
| Prednisone | Drug | Prednisone | ALIAS |
| YM 155 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1. HRPC
- interventionNames
- Drug: YM 155
- Drug: Docetaxel
- Drug: Prednisone
- type
- EXPERIMENTAL
- label
- 2. Solid Tumors
- interventionNames
- Drug: YM 155
- Drug: Docetaxel
Primary outcomes (2)
- measure
- Occurrence of dose limiting toxicities (Part 1: Subjects with HRPC)
- timeFrame
- 2 cycles
- measure
- Occurrence of dose limiting toxicities (Part 2: Subjects with other solid tumors)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Part 1: * Male subjects with histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiological evidence of metastatic disease. Part 2: * Subjects with histologically and cytologically confirmed solid tumors with measurable disease (except HRPC). Exclusion Criteria: * Radiation therapy within 4 weeks of the start of study drug
References
Publications (0)
Data not yet available
No reference posted for this study.